Respiratory Syncytial Virus Vaccines
"Respiratory Syncytial Virus Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
| Descriptor ID |
D022261
|
| MeSH Number(s) |
D20.215.894.899.730
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus Vaccines".
This graph shows the total number of publications written about "Respiratory Syncytial Virus Vaccines" by people in this website by year, and whether "Respiratory Syncytial Virus Vaccines" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
Below are the most recent publications written about "Respiratory Syncytial Virus Vaccines" by people in Profiles.
-
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates. JAMA Netw Open. 2025 Feb 03; 8(2):e2460735.
-
Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment. Obstet Gynecol Surv. 2024 Oct; 79(10):585-590.
-
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020. Clin Infect Dis. 2024 May 15; 78(5):1352-1359.
-
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019. J Pediatr. 2024 Aug; 271:114045.
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
-
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children. J Infect Dis. 2022 12 13; 226(12):2069-2078.
-
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. N Engl J Med. 2022 04 28; 386(17):1615-1626.
-
Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children. Am J Respir Crit Care Med. 2021 03 01; 203(5):594-603.
-
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children. J Infect Dis. 2020 06 11; 221(12):2050-2059.
-
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. J Infect Dis. 2020 02 03; 221(4):534-543.